About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
exaly
›
Institutions
›
University of Texas MD Anderson Cancer Center
›
Department of Gynecologic Oncology and Reproductive Medicine
›
Top Articles
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
18.8K
Articles
720.6K
Citations
3.1
avg. Impact Factor
316
h-index
Most Cited Articles of Department of Gynecologic Oncology and Reproductive Medicine in 2017
Title
Journal
Year
Citations
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Cell
2017
2.1K
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
JAMA Oncology
2017
1.4K
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Ca-A Cancer Journal for Clinicians
2017
1K
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncology, The
2017
981
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
New England Journal of Medicine
2017
978
Integrated genomic characterization of oesophageal carcinoma
Nature
2017
965
The Human Cell Atlas
ELife
2017
937
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Cell
2017
831
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet, The
2017
815
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Cancer Cell
2017
680
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Cell
2017
659
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Blood
2017
653
Association analysis identifies 65 new breast cancer risk loci
Nature
2017
643
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Science
2017
577
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
New England Journal of Medicine
2017
487
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Clinical Cancer Research
2017
460
2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction
Heart Rhythm
2017
454
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Science Translational Medicine
2017
409
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Cancer Cell
2017
391
Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Lancet Oncology, The
2017
389
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Molecular Therapy
2017
370
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Annals of Oncology
2017
361
GlioVis data portal for visualization and analysis of brain tumor expression datasets
Neuro-Oncology
2017
340
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Lancet Oncology, The
2017
318
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Nature Medicine
2017
316
Schools/Departments
The list of schools/departments is not comprehensive since it is common to drop the department in the affiliation.
site/software ©
exaly
; All materials licenced under
CC by-SA
.